Lite Strategy (NASDAQ:LITS) Stock Bumped Down to “Strong Sell” by Wall Street Zen

Wall Street Zen downgraded shares of Lite Strategy (NASDAQ:LITS – Free Report) from a hold rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded Lite Strategy from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Lite Strategy has an average rating of “Sell”.

View Our Latest Research Report on Lite Strategy

Lite Strategy Trading Down 4.6%

Shares of Lite Strategy stock opened at $0.80 on Friday. Lite Strategy has a twelve month low of $0.69 and a twelve month high of $1.99. The firm has a market capitalization of $23.85 million, a PE ratio of -0.58 and a beta of 0.17. The firm’s 50-day moving average price is $1.14 and its 200 day moving average price is $1.07.

Lite Strategy (NASDAQ:LITS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.48 EPS for the quarter.

Hedge Funds Weigh In On Lite Strategy

Several institutional investors and hedge funds have recently bought and sold shares of LITS. ADAR1 Capital Management LLC purchased a new stake in shares of Lite Strategy in the 2nd quarter valued at approximately $62,000. BlackRock Inc. acquired a new position in Lite Strategy during the 2nd quarter worth about $254,000. GSA Capital Partners LLP acquired a new position in Lite Strategy during the 2nd quarter worth about $57,000. Finally, Renaissance Technologies LLC lifted its stake in Lite Strategy by 13.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,744,700 shares of the company’s stock worth $2,024,000 after acquiring an additional 203,278 shares in the last quarter. 52.38% of the stock is currently owned by institutional investors and hedge funds.

Lite Strategy Company Profile

(Get Free Report)

Lite Strategy, Inc. is a digital-asset treasury company focused on acquiring and holding Litecoin as a primary reserve asset. Its business centers on managing this Litecoin-focused strategy rather than providing consumer products or services. The company was formerly known as MEI Pharma, a clinical-stage biopharmaceutical company that worked on treatments for cancer. It later shifted its business focus to a Litecoin treasury strategy. Lite Strategy’s activities therefore primarily involve its digital-asset holdings and related treasury management; the company is not principally engaged in drug development under its current strategy.

See Also

Receive News & Ratings for Lite Strategy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lite Strategy and related companies with MarketBeat.com's FREE daily email newsletter.